GlassScriptPhysician profile
Brooke A Lowell
NPI 1538122064
$3,428.60
in general payments reported to CMS, 2019-2025
23 companies · $713 in 2025
The $713 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $186 · 2021: $472 · 2022: $409 · 2023: $653 · 2024: $680 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,037 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.34 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,542.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $370.04 | 2019-2025 | |
| Genzyme Corporation | $218.66 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $195.80 | 2020-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $145.15 | 2022-2025 | Nemluvio, Aklief, Oracea |
| Sun Pharmaceutical Industries INC. | $110.49 | 2021-2025 | Blu-U |
| Amgen INC. | $104.91 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $91.11 | 2021-2025 | Ebglyss, Taltz |
| Incyte Corporation | $85.90 | 2022-2025 | Opzelura |
| Ucb, INC. | $85.77 | 2020-2024 | Bimzelx |
| Janssen Biotech, INC. | $85.51 | 2020-2025 | Tremfya |
| Leo Pharma INC. | $80.01 | 2021-2025 | Adbry, Spevigo |
| E.R. Squibb & Sons, L.L.C. | $75.80 | 2022-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.33 | 2022-2023 | Spevigo |
| Biofrontera INC. | $34.48 | 2021-2025 | Ameluz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $29.25 | 2019 | |
| Vyne Pharmaceuticals INC. | $26.01 | 2020 | |
| Mayne Pharma Commercial LLC | $21.23 | 2019 | |
| Pfizer INC. | $19.14 | 2023 | |
| Dermavant Sciences, INC. | $18.99 | 2023 | Vtama |
| Almirall LLC | $15.33 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.75 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Lowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.